Blue Jet Healthcare
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Blue Jet Healthcare is strategically pivoting towards high-growth segments such as GLP-1 therapeutics and peptide fragments, which are expected to mitigate the impact of genericization and market volatility. Management's positive outlook is supported by the expansion of their CDMO footprint and the commissioning of the Vizag R&D facility, anticipated to drive long-term growth. Despite facing short-term revenue recognition challenges due to logistics delays, the underlying demand remains stable, bolstered by a robust order book. Vista's financial outlook reflects early revenue recovery and stable margins, with a target price indicating an expected upside of approximately 19.5%. The industry context is favorable, with improving pricing power and significant growth potential for Indian CDMOs, although risks such as raw material price volatility and regulatory compliance remain. Over the next 12-24 months, key opportunities include the successful scaling of the Vizag facility and the diversification into high-margin segments, while watchpoints include potential pricing pressures in the peptide market and execution risks associated with new product ramp-ups
Why We Like This Stock
- Strategic pivot towards high-growth segments like GLP-1 therapeutics and peptides enhances long-term growth prospects
- Expansion of the Vizag R&D facility is expected to drive revenue recovery and diversification into high-margin products
- Improving pricing power in the industry supports margin stability and overall profitability
Things To Watch Out For
- Short-term revenue recognition challenges due to logistics delays may impact financial performance
- Raw material price volatility poses risks to margins and earnings estimates
- Execution risks related to scaling new, high-complexity chemistry platforms could hinder growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 712 | 1,030 | 947 | 1,017 | 1,108 |
| Profit Before Tax (Cr.) | 230 | 398 | 333 | 370 | 399 |
| PBT Margin | 32.3% | 38.6% | 35.2% | 36.4% | 36.0% |
| Net Profit (Cr.) | 173 | 303 | 251 | 281 | 303 |
| Earnings Per Share | 10.0 | 17.5 | 14.5 | 16.2 | 17.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Motilal Oswal | ▲ Buy | 720 | 18-Aug-2026 |
| ICICI Securities | ▲ Buy | 680 | 04-Aug-2026 |
| JPMorgan | ▼ Reduce | 370 | 26-May-2026 |
| Kotak Securities | ► Add | 505 | 26-May-2026 |
Company Overview
Show Company Profile
Blue Jet Healthcare Limited engages in the manufacturing and sale of artificial sweeteners, pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in products. It provides contrast media intermediates, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related supplies to healthcare, pharma, animal feed, and food and beverages industries. It has operations in India, Norway, France, the United States, Denmark, Thailand, Spain, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.